Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
30 hedge funds and large institutions have $34.3M invested in Carisma Therapeutics in 2015 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 17 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
14% less capital invested
Capital invested by funds: $40M → $34.3M (-$5.71M)
27% less funds holding
Funds holding: 41 → 30 (-11)
65% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.39M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$611K |
| 3 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
+$588K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$529K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$359K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.06M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$1.27M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$273K |
| 4 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
-$212K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$122K |
CARM Hedge Fund Activity: Q3 2015 in Review
30 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q3 2015, worth a combined $34.3M — down 14% from $40M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CARM and 6 opened new positions — a net loss of 11 holders — while 7 trimmed existing stakes and 8 added.
The largest buyer was Federated Hermes, opening a new position worth an estimated $2.39M. The largest seller was OrbiMed, exiting entirely with an estimated $2.06M sold.
- 30 institutional investors held Carisma Therapeutics (CARM) as of Q3 2015, down from 41 in Q2 2015.
- Funds reported $34.3M of Carisma Therapeutics stock for Q3 2015, down 14% quarter-over-quarter.
- 6 funds opened new Carisma Therapeutics positions in Q3 2015 and 17 closed out, a net change of -11 holders.
- The largest Carisma Therapeutics buyer in Q3 2015 was Federated Hermes, an estimated $2.39M added.
- The largest Carisma Therapeutics seller in Q3 2015 was OrbiMed, an estimated $2.06M sold.
Based on aggregated 13F filings for Q3 2015.